Systematic Reviews
Copyright ©The Author(s) 2023.
World J Crit Care Med. Mar 9, 2023; 12(2): 71-88
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Table 2 Multiple logistic regression analysis to predict 30 d mortality
Ref.
Study design
Population
Intervention
Outcomes
Friesecke et al[62], 2017 Prospective, single center study20 septic shock patientsCytoSorb hemoperfusionNorepinephrinedose reduced after 6 and 12 h; Improved lactate clearance; SOFA scores unchanged; Shock reversal achieved in 65% of patients; 28-d survival – 45%
Kogelmann et al[63], 2017Case series26 septic shock patientsCytoSorb+CVVHDRapid hemodynamic stabilization; Reduction in Vasopressor dose by 67%; Decrease in blood lactate by 26.4%; Shock reversal in 38.5% patients; Decreased mortality than predicted by APACHE II; No adverse events reported
Friesecke et al[52], 2017International registry135 septic shock patientsCytoSorb hemoperfusionReduced observed mortality of 65% than predicted by APACHE II of 78%; Marked reduction in IL6 levels; No significant reduction in SOFA scores; Safe and well tolerated without any adverse events
Brouwer et al[59], 2019Retrospective, investigator-initiated study116 septic shock patientsCytoSorb +CRRTIn CytoSorb group, the mean predicted mortality rate was 74.5%, while 28 d mortality rate was 47.8%; In CRRT group, the mean predicted mortality rate was 67.9%, while 28-d mortality was 51.0%; CytoSorb group was associated with a reduced 28-d mortality in comparison to CRRT (53% vs 72.3%)
CRRT alone
Brouwer et al[60], 2021Long term follows up116 septic shock patientsCytoSorb +CRRTCytoSorb was significantly associated with long term outcome compared to CRRT
Retrospective cohort studyCRRT alone
Mehta et al[53], 2020Retrospective, observational study40 septic shock patientsCytoSorb hemoperfusion (Survivor group vs non survivor group)Improvement in MAP (62.82 ± 9.73mmHg); Reduction in vasopressor dose; Reduction IL-6 levels (87%) and TNF levels (24%); Decrease in SOFA scores by 16.2%
Paul et al[68], 2021Prospective, real time, observational multicentre study45 septic shock patientsCytoSorb+ Standard therapy26 patients survived post therapy; Reduction in vasopressor dose (NE- 51.4%, Epinephrine – 69.4% and Vasopressin -13.9%); 52.3% reduction in IL-6 levels; Reduction in APACHE II and SOFA scores, 20.1 ± 2.47 and 9.04 ± 3.00 respectively
(Survivor vs non survivor group)
Akil et al[69], 202020 patients with pneumogenic sepsis and ARDSCytoSorb + Combined high flow veno-venous ECMO (CytoSorb group); ECMO therapy alone (Control group)The 30-d mortality rate was 0% in CytoSorb group, whereas 57% was observed in control group; Significant reduction in procalcitonin and C-reactive levels were observed in CytoSorb group in comparison to control group
Rugg et al[61], 2020Retrospective single center study42 septic shock patients compared to 42 matched controlsCytosorb +RRTCatecholamines requirements decreased to 0.26 µg/kg/min within 24 h of therapy with CytoSorb; In hospital mortality was significantly lower in CytoSorb group as compared to controls (35.7% vs 61.9%); Risk factors in CytoSorb group were high lactate levels and low thrombocyte counts proior to therapy. Lactate value of 7.5 mmol/L, predicted mortality with high specificicty (88.9%)